CODEINE SULFATE Drug Patent Profile
✉ Email this page to a colleague
When do Codeine Sulfate patents expire, and when can generic versions of Codeine Sulfate launch?
Codeine Sulfate is a drug marketed by Hikma and Lannett Co Inc and is included in three NDAs.
The generic ingredient in CODEINE SULFATE is codeine sulfate. There are nineteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the codeine sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Codeine Sulfate
A generic version of CODEINE SULFATE was approved as codeine sulfate by HIKMA on July 16th, 2009.
Summary for CODEINE SULFATE
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 3 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 14 |
Clinical Trials: | 8 |
Patent Applications: | 1,047 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for CODEINE SULFATE |
What excipients (inactive ingredients) are in CODEINE SULFATE? | CODEINE SULFATE excipients list |
DailyMed Link: | CODEINE SULFATE at DailyMed |
Recent Clinical Trials for CODEINE SULFATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Sao Paulo General Hospital | Phase 3 |
Aristotle University Of Thessaloniki | Phase 4 |
Quintiles, Inc. | Phase 3 |
Pharmacology for CODEINE SULFATE
Drug Class | Opioid Agonist |
Mechanism of Action | Full Opioid Agonists |